(A) Cumulative incidence of detection of quantifiable CMV according to use of letermovir as prophylaxis. (B) Cumulative incidence of clinically significant CMV infection. (C) Cumulative incidence of preemptive CMV therapy in patients who received letermovir by donor type. (D) Cumulative incidence of clinically significant CMV infection in patients receiving letermovir with at least 14 weeks follow-up according to GVHD severity. UD, unrelated donor.